| Schedule (route) | Endpoint | Vehicle | Dose | Treated/Control (%) | Observations |
|---|---|---|---|---|---|
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 6.25 mg/kg/injection | 111.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 12.5 mg/kg/injection | 122.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 25.0 mg/kg/injection | 139.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 25.0 mg/kg/injection | 151.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 50.0 mg/kg/injection | 168.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 50.0 mg/kg/injection | 159.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 100.0 mg/kg/injection | 182.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 100.0 mg/kg/injection | 193.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 200.0 mg/kg/injection | 93.0 | Antitumor endpoint evaluated on day 30; 06/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 200.0 mg/kg/injection | 121.0 | Antitumor endpoint evaluated on day 30; 05/06 animals surviving on day 5 |
| Q01DX009 (ip) | median survival time | saline with Tween-80 | 400.0 mg/kg/injection | 0.0 | Antitumor endpoint evaluated on day 30; 04/06 animals surviving on day 5 |